Cardiometabolic Multimorbidity in Older Adults: Risk Assessment, Individualised Treatment, and Evidence Gaps

Cardiometabolic multimorbidity, encompassing combinations of hypertension, diabetes, dyslipidaemia, obesity, and cardiovascular disease, is highly prevalent in older adults and drives excess mortality, disability, and healthcare utilisation. Yet, older adults—especially those ≥75 years with frailty, multimorbidity, or cognitive impairment—remain underrepresented in pivotal cardiometabolic randomised trials, limiting the applicability of current risk scores, treatment thresholds, and guideline recommendations to geriatric patients. This narrative review synthesises the contemporary evidence on cardiometabolic medicine in older adults, highlighting the gaps in epidemiology, risk stratification, therapeutic decision-making, and patient-centred outcomes. Emerging data confirm that the clustering of cardiometabolic risk factors is associated with steeply increased risks of sudden cardiac death, heart failure, and all-cause mortality in ageing populations, but robust intervention trials targeting these clusters in older, frail individuals are scarce. Furthermore, evidence for newer pharmacologic agents (such as SGLT2 inhibitors, GLP-1 receptor agonists, and PCSK9 inhibitors) in the oldest-old with functional impairment and polypharmacy is limited, leading to wide practice variation and frequent extrapolation from younger cohorts. The review is structured thematically to address the following: the epidemiology and phenotypes of cardiometabolic multimorbidity in older adults; the limitations of existing risk models and guideline targets; challenges in balancing intensive treatment with risks of adverse events and functional decline; and the role of frailty, comorbidity, and patient preferences in clinical decision-making. Finally, it outlines research priorities, including pragmatic geriatric-focused trials, the incorporation of frailty and function into cardiometabolic guidelines, and the development of real-world registries, to inform individualised treatment and de-intensification strategies in this rapidly growing population.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-20
DOI
https://doi.org/10.3390/jcm15229115
Primary Topic
Chronic Disease Management Strategies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cardiometabolic Multimorbidity in Older Adults: Risk Assessment, Individualised Treatment, and Evidence Gaps

Marilena Giannoudi, Christos Fragoulis, Konstantinos P Tsioufis, Vasileios Kordalis et al.
4 links
Journal of Clinical Medicine
Chronic Disease Management Strategies
article

Cardiometabolic Multimorbidity in Older Adults: Risk Assessment, Individualised Treatment, and Evidence Gaps

Marilena Giannoudi, Christos Fragoulis, Konstantinos P Tsioufis, Vasileios Kordalis, Vasiliki Katsi
article en

Abstract

Cardiometabolic multimorbidity, encompassing combinations of hypertension, diabetes, dyslipidaemia, obesity, and cardiovascular disease, is highly prevalent in older adults and drives excess mortality, disability, and healthcare utilisation. Yet, older adults—especially those ≥75 years with frailty, multimorbidity, or cognitive impairment—remain underrepresented in pivotal cardiometabolic randomised trials, limiting the applicability of current risk scores, treatment thresholds, and guideline recommendations to geriatric patients. This narrative review synthesises the contemporary evidence on cardiometabolic medicine in older adults, highlighting the gaps in epidemiology, risk stratification, therapeutic decision-making, and patient-centred outcomes. Emerging data confirm that the clustering of cardiometabolic risk factors is associated with steeply increased risks of sudden cardiac death, heart failure, and all-cause mortality in ageing populations, but robust intervention trials targeting these clusters in older, frail individuals are scarce. Furthermore, evidence for newer pharmacologic agents (such as SGLT2 inhibitors, GLP-1 receptor agonists, and PCSK9 inhibitors) in the oldest-old with functional impairment and polypharmacy is limited, leading to wide practice variation and frequent extrapolation from younger cohorts. The review is structured thematically to address the following: the epidemiology and phenotypes of cardiometabolic multimorbidity in older adults; the limitations of existing risk models and guideline targets; challenges in balancing intensive treatment with risks of adverse events and functional decline; and the role of frailty, comorbidity, and patient preferences in clinical decision-making. Finally, it outlines research priorities, including pragmatic geriatric-focused trials, the incorporation of frailty and function into cardiometabolic guidelines, and the development of real-world registries, to inform individualised treatment and de-intensification strategies in this rapidly growing population.

Journal of Clinical MedicineVol. 15(22)
University of Leeds (GB), National and Kapodistrian University of Athens (GR), Aristotle University of Thessaloniki (GR), Hippocration General Hospital (GR)
Good health and well-being
Chronic Disease Management Strategies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon